BIOLASE Competitors

BIOLASE (NASDAQ:BIOL) and Urovant Sciences (NASDAQ:UROV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Risk and Volatility

BIOLASE has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500.

Valuation and Earnings

This table compares BIOLASE and Urovant Sciences' top-line revenue, earnings per share (EPS) and valuation.

BIOLASE has higher revenue and earnings than Urovant Sciences. Urovant Sciences is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BIOLASE and Urovant Sciences' net margins, return on equity and return on assets.

Institutional and Insider Ownership

5.5% of BIOLASE shares are owned by institutional investors. Comparatively, 18.4% of Urovant Sciences shares are owned by institutional investors. 2.2% of BIOLASE shares are owned by company insiders. Comparatively, 2.7% of Urovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for BIOLASE and Urovant Sciences, as provided by MarketBeat.

BIOLASE currently has a consensus price target of $2.00, indicating a potential upside of 120.46%. Urovant Sciences has a consensus price target of $16.1667, indicating a potential downside of 0.02%. Given BIOLASE's stronger consensus rating and higher possible upside, analysts clearly believe BIOLASE is more favorable than Urovant Sciences.

Summary

BIOLASE beats Urovant Sciences on 8 of the 13 factors compared between the two stocks.

BIOLASE (NASDAQ:BIOL) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Risk and Volatility

BIOLASE has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.

Valuation and Earnings

This table compares BIOLASE and Clovis Oncology's gross revenue, earnings per share and valuation.

BIOLASE has higher earnings, but lower revenue than Clovis Oncology. BIOLASE is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BIOLASE and Clovis Oncology's net margins, return on equity and return on assets.

Institutional & Insider Ownership

5.5% of BIOLASE shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 2.2% of BIOLASE shares are held by insiders. Comparatively, 6.6% of Clovis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for BIOLASE and Clovis Oncology, as reported by MarketBeat.com.

BIOLASE currently has a consensus price target of $2.00, suggesting a potential upside of 120.46%. Clovis Oncology has a consensus price target of $8.80, suggesting a potential upside of 46.91%. Given BIOLASE's stronger consensus rating and higher probable upside, equities research analysts clearly believe BIOLASE is more favorable than Clovis Oncology.

Summary

Clovis Oncology beats BIOLASE on 8 of the 14 factors compared between the two stocks.

BIOLASE (NASDAQ:BIOL) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Valuation and Earnings

This table compares BIOLASE and Landos Biopharma's gross revenue, earnings per share and valuation.

Landos Biopharma has lower revenue, but higher earnings than BIOLASE.

Profitability

This table compares BIOLASE and Landos Biopharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

5.5% of BIOLASE shares are held by institutional investors. 2.2% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for BIOLASE and Landos Biopharma, as reported by MarketBeat.com.

BIOLASE currently has a consensus price target of $2.00, suggesting a potential upside of 120.46%. Given BIOLASE's higher probable upside, equities research analysts clearly believe BIOLASE is more favorable than Landos Biopharma.

Summary

BIOLASE beats Landos Biopharma on 5 of the 8 factors compared between the two stocks.

BIOLASE (NASDAQ:BIOL) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BIOLASE and Altimmune, as reported by MarketBeat.com.

BIOLASE currently has a consensus price target of $2.00, suggesting a potential upside of 120.46%. Altimmune has a consensus price target of $31.75, suggesting a potential upside of 99.18%. Given BIOLASE's higher possible upside, research analysts plainly believe BIOLASE is more favorable than Altimmune.

Earnings & Valuation

This table compares BIOLASE and Altimmune's top-line revenue, earnings per share and valuation.

BIOLASE has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BIOLASE and Altimmune's net margins, return on equity and return on assets.

Risk and Volatility

BIOLASE has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Insider & Institutional Ownership

5.5% of BIOLASE shares are owned by institutional investors. Comparatively, 66.2% of Altimmune shares are owned by institutional investors. 2.2% of BIOLASE shares are owned by insiders. Comparatively, 2.7% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

BIOLASE beats Altimmune on 7 of the 13 factors compared between the two stocks.

Amryt Pharma (NASDAQ:AMYT) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Amryt Pharma and BIOLASE's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Amryt Pharma and BIOLASE, as provided by MarketBeat.com.

Amryt Pharma currently has a consensus target price of $41.6667, indicating a potential upside of 182.68%. BIOLASE has a consensus target price of $2.00, indicating a potential upside of 120.46%. Given Amryt Pharma's higher probable upside, equities analysts clearly believe Amryt Pharma is more favorable than BIOLASE.

Insider and Institutional Ownership

15.4% of Amryt Pharma shares are held by institutional investors. Comparatively, 5.5% of BIOLASE shares are held by institutional investors. 2.2% of BIOLASE shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Amryt Pharma and BIOLASE's gross revenue, earnings per share (EPS) and valuation.

BIOLASE has lower revenue, but higher earnings than Amryt Pharma. Amryt Pharma is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats BIOLASE on 8 of the 13 factors compared between the two stocks.

Biodesix (NASDAQ:BDSX) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Institutional & Insider Ownership

5.5% of BIOLASE shares are held by institutional investors. 2.2% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Biodesix and BIOLASE, as provided by MarketBeat.

Biodesix currently has a consensus target price of $24.3333, indicating a potential upside of 23.27%. BIOLASE has a consensus target price of $2.00, indicating a potential upside of 120.46%. Given BIOLASE's higher possible upside, analysts plainly believe BIOLASE is more favorable than Biodesix.

Valuation & Earnings

This table compares Biodesix and BIOLASE's top-line revenue, earnings per share (EPS) and valuation.

Biodesix has higher earnings, but lower revenue than BIOLASE.

Profitability

This table compares Biodesix and BIOLASE's net margins, return on equity and return on assets.